Search the Newsreel

Seres Therapeutics Q2 Net Income Reaches $4.6 Million

Seres Therapeutics (MCRB) reported a net income of $4.6 million in Q2 2026, a significant improvement from a net loss of $19.9 million in the prior year, primarily due to a $25 million gain from the sale of its VOWST business. The company also …

Seres Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates, Including Further Action to Reduce Ongoing Facilities Costs

Seres Therapeutics announced its second quarter 2026 financial results, highlighting positive topline data from its SER-155 trial for immune checkpoint inhibitor-related enterocolitis (irEC) and reporting 80% immunosuppressive-free clinical response at day 15. The company is actively seeking partners and capital to advance its SER-155 …

Seres Therapeutics: Q2 Earnings Snapshot

Seres Therapeutics Inc. reported a profit of $4.6 million, or 47 cents per share, in its second quarter. The drug developer's losses, when adjusted for non-recurring gains, were $1.50 per share. Revenue for the period was $736,000.

Seres Therapeutics Inc expected to post a loss of $2.18 a share - Earnings Preview

Seres Therapeutics Inc is projected to report an earnings loss of $2.18 per share. This information comes from an earnings preview provided by Refinitiv. The article focuses on the preliminary financial expectations for the company.

Seres Therapeutics Inc (MCRB) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Seres Therapeutics Inc (MCRB), highlighting its current price momentum score as 5.77 within the Biotechnology & Medical Research industry. It identifies the stock's support level at $3.41 and resistance level at $7.07, suggesting suitability for range-bound swing …

MCRB Q2'26 Earnings: revenue estimate is 179.00K USD

Seres Therapeutics, Inc. (MCRB) is projected to release its Q2'26 earnings on August 5th, with an estimated revenue of $179.00 thousand and an anticipated EPS of ($2.19) USD. The article provides historical revenue and EPS data alongside these estimates, noting past surprises in both …

MCRB|Seres Therapeutics Inc|Price:4.755|Chg%:-0.045

This article provides a comprehensive stock analysis of Seres Therapeutics Inc (MCRB) by TradingKey, highlighting its relatively stable fundamentals, high growth potential, and "fairly valued" status within the Biotechnology & Medical Research industry. It notes very high institutional ownership and multiple "Buy" ratings from …

Seres Therapeutics Inc (MCRB) Dividends & Stock Splits: Historical Payouts and Event Timeline

The article provides a historical overview of Seres Therapeutics Inc (MCRB) regarding its dividend payouts and stock splits. It states that the company has distributed $0.00 in dividends over the past five years and lists a future merger event with a 20:1 ratio scheduled …

Seres Therapeutics Inc (MCRB) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Seres Therapeutics Inc (MCRB), highlighting its current earnings forecast score, average price target, and analyst ratings. Based on two analysts, the stock has a "Buy" recommendation with an average target price of $21.00. The report also details …

Seres Therapeutics Inc (MCRB) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article provides a revenue breakdown for Seres Therapeutics Inc (MCRB), detailing its business segments, regional revenue, and profit contributions. As of the report, relevant data for FY2021-FY2025 have not been disclosed by the company. The only specific regional revenue figure provided is for …

Seres Therapeutics Inc (MCRB) Financial Health: Profitability & Balance Sheet Analysis

This article provides a financial health analysis of Seres Therapeutics Inc (MCRB), indicating a current financial score of 5.80, which ranks 326 out of 386 in the Biotechnology & Medical Research industry. The company's financial status is described as weak with low operating efficiency. …

Seres Therapeutics (MCRB) H.C. Wainwright 4th Annual BioConnect Investor Conference summary

Seres Therapeutics presented a summary of their drug technology and pipeline at the H.C. Wainwright 4th Annual BioConnect Investor Conference. They highlighted their novel drug technology using bacterial consortia, leading to the first FDA-approved oral microbiome drug with an 88% sustained response for C. …

Seres Therapeutics (MCRB) Q1 2026 Earnings: EPS Misses Estimates as Stock Declines 8.1%

Seres Therapeutics (MCRB) awards 7,500 stock options to company officer Marella Thorell

Seres Therapeutics (MCRB) awards 6,500 stock options to director Stephen Berenson

Seres Therapeutics (MCRB) awards 50,000 stock options to director-officer

Seres Therapeutics (MCRB) awards 6,500-share stock option grant to director Dere

MCRB Q1 2026 Earnings: EPS Miss and No Revenue as Pipeline Progress Awaited - SaaS Earnings Trends

Seres Therapeutics (MCRB) Q1 2026 Earnings: Wider-than-Expected Loss as Pipeline Development Continues - Earnings Power Value

Here's Why We're A Bit Worried About Seres Therapeutics' (NASDAQ:MCRB) Cash Burn Situation

MCRB Q1 2026 Earnings: EPS Falls Short as Clinical-Stage Focus Continues - Preliminary Results

Seres Therapeutics, Inc. (MCRB) Stock Price, News, Quote & History

Mark Your Calendar: Leading Biotherapeutics Company Seres Therapeutics Announces Q2 2025 Earnings Date

Seres Therapeutics (MCRB) Earnings Date and Reports 2026

Seres Therapeutics, Inc. (MCRB) stock price, news, quote and history

Seres Therapeutics (MCRB) Stock Price, News & Analysis

Should I buy Seres Therapeutics (MCRB)

Seres Therapeutics (MCRB)